Rivaroxaban and Acute Coronary Syndrome

Acute coronary syndrome is simply a blanket term that encompasses cardiac incidents in which blood flow to the heart is disturbed. This could include a heart attack, unstable angina, or simply mean clotting in the arteries. Many of these episodes are fatal or can cause permanent damage to the heart.

Chest pain is the main warning sign associated with acute coronary syndrome. Other common signs of heart problems include discomfort in the limbs, shortness of breath, dizziness, nausea, or sweating. The symptoms may come and go, be sudden, or cause continuous pain.

Xarelto, an anticoagulant manufactured by Johnson & Johnson and Bayer, was prescribed to treat acute coronary syndrome to prevent blood clots from forming. However, according to the website of the attorneys at Williams Kherkher, Xarelto may not be a viable option to treating acute coronary syndrome due to the serious side effects that it is reported to cause. While the drug is still prescribed for short-term use in acute coronary syndrome cases in the United Kingdom, the U.S. Food and Drug Administration advisory committee have consistently denied the approval of Xarelto for that purpose.

A trial to test rivaroxaban in acute coronary syndrome cases took place to challenge the FDA’s ruling against the use of Xarelto. ATLAS ACS 2-TIMI 51 tested the effectiveness of very-low doses of Xarelto at 2.5 mg twice daily in trial patients. It was found that the drug reduced the risk for cardiovascular related death in reference to the placebo. However, the excess risk of bleeding was also found in users of the drug.

Over the course of 31 months, 15,526 patients with a recent episode of cardiovascular problems were given the placebo, 2.5 mg, or 5 mg of rivaroxaban. At the end of the trial, the instances of cardiovascular death, heart failure, and stroke. The treatment worked best with young, healthier patients rather than the predominant older population suffering from cardiovascular health concerns that were more likely to experience bleeding incidents. The FDA is currently investigating Xarelto for its increased risk of serious bleeding incidents.


Leave a Reply

Your email address will not be published. Required fields are marked *